热门资讯> 正文

CRISPR Therapeutics股价因3.5亿美元可转换债券发行而下跌

2026-03-10 19:07

CRISPR Therapeutics AG(CRSP) 0
易昆尼克斯(EQIX) 0

CRISPR Therapeutics (CRSP) plans to offer $350M aggregate principal amount of its convertible senior notes due 2031 in a private offering.
The company also expects to grant the initial purchasers a 13-day option to purchase up to an additional $52.5M aggregate principal amount of the notes.
The notes will accrue interest payable semiannually and will mature on March 1, 2031, unless earlier converted, redeemed, or repurchased.
The biopharmaceutical company plans to use the net proceeds from the offering for general corporate purposes.
CRSP shares fell -6.5% premarket to $54.94.

More on CRISPR Therapeutics

Is A Vertex Buyout Of Crispr Therapeutics Inevitable? Here's My Take
Crispr Therapeutics: Very High Risk, But Even Higher Potential Reward
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Key deals this week: KORE, TopBuild, Equinix, PayPal and more
Crispr Therapeutics gains amid takeover speculation

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。